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1. Introduction 
Adherence to long-term therapy is a challenge for patients worldwide. In developing 
countries the focus is placed on adherence to antiretroviral treatment for HIV and 
antibacterial treatment for TB, while patients and health care providers in developed 
countries grapple with adherence to treatment of chronic lifestyle diseases such as diabetes. 
Adherence is a crucial element of successful treatment – some say it is the backbone of any 
medical treatment. It is therefore of utmost importance for health care providers to assess 
how adherent their patients are. However, this is often overlooked in routine patient 
assessments in primary care.  
This chapter describes the challenges of adherence with long-term treatments by using the 
example of antiretroviral treatment for HIV. It introduces the most common adherence 
measures and describes the experiences of integrating adherence assessment in primary 
health care settings in Cape Town, South Africa. Even though it focuses on adherence in 
pediatric patients, the observations and conclusions drawn from this chapter are highly 
relevant to any age group.  
2. Adherence - “Drugs don't work in patients who don't take them”
1
 
Chronically ill patients need to take medication for the rest of their life. This requires a lot of 
discipline and commitment from the patients’ part, as well as good education and 
communication from the health care providers’ side. In the past, the term “compliance” was 
used to characterize the patients’ following of health care providers’ instructions. As models 
of patient-physician relationship have changed, so has the definition of “compliance”. The 
new definition challenges the often paternalistic model of decision-making and emphasizes 
a more equal cooperation between patient and health care provider. The term “compliance” 
has been replaced with “adherence”, to acknowledge the patient’s more active participation 
in the decision-making process and seeing medication-taking behaviour from the patient’s 
perspective: “Adherence is the engaged and accurate participation of an informed patient in 
                                                 
1 Quote by C. EVERETT KOOP, Professor of Pediatrics and Paediatric Surgery, University of 
Pennsylvania; Surgeon General of the United States 1982 – 1989, quoted in: OSTERBERG and 
BLASCHKE (2005; p. 487) 
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a plan of care. It is a broader term than compliance – the extent to which patients follow the 
instructions of their healthcare providers – and implies understanding, consent, and 
partnership. Adherence includes entering into and continuing in a program or care plan, 
attending appointments and tests as scheduled, taking medications as prescribed, modifying 
lifestyle as needed, and avoiding risk behaviours. It includes adherence to care and 
adherence to medication, but is usually regarded as more than the sum of its parts.”2. 
Osterberg and Blaschke (2005) further elaborate on the difference between compliance and 
adherence: “The word “adherence” is preferred by many health care providers, because 
“compliance” suggests that the patient is passively following the doctor’s orders and that 
the treatment plan is not based on a therapeutic alliance or contract established between the 
patient and the physician.” The World Health Organization suggests broadening the 
definition of the term adherence to “the extent to which a person’s behaviour – taking 
medication, following a diet, and/or executing lifestyle changes, corresponds with agreed 
recommendations from a health care provider” (WHO 2003; p. 3), according to Berg and 
Arnsten (2006; p. S79), this behaviour is “individual, complex and dynamic”. Table 1 
illustrates the various dimensions of adherence, and each dimension’s correlate in the 
patient’s behaviour. 
 
Adherence Behaviour Behavioural Task 
Medication-refill adherence Patient picks up a prescription refill 
Medication-interval adherence Patient takes a medication at the right time of the day 
Medication-quantity adherence Patient takes the right number of pills 
Medication-diet adherence Patient takes medication in accordance with dietary 
requirements (if specified) 
Table 1. Dimensions of adherence 
Contrary to this concept, clinical practice often limits the term adherence to the intake of 
medication and disregards the broader implications of its definition. Adherence is usually 
reported as the percentage of the prescribed doses actually taken by the patient over a 
specified period of time, and thus reduced to recommendations that instruct the patient on 
tablet intake. For these instructions, adherence can vary along a continuum from 0 to 100 
percent, sometimes over 100 percent if patients take more than the prescribed amount of 
medication. Adherence can also be reported as a dichotomous variable, classifying patients 
into the categories adherent or non-adherent. Since there is no consensual standard for what 
constitutes adequate adherence, the cut-off value for these categories depends on the 
patient’s condition, the characteristics of the regimen prescribed, on pharmacokinetics of the 
prescribed medication and on individual research protocols. For HIV infection, an 
adherence rate greater than 95 percent is considered adequate and necessary for treatment 
success (Chesney 2003; Paterson et al. 2000). However, common to all these definitions of 
adherence is the fact that they solely focus on the intake of medication and do not allow for 
an inclusion of dietary instructions, lifestyle changes or general health behaviour of patients. 
In the industrialised world, adherence has been in the focus for medication of chronic 
diseases such as diabetes and hypertension, or for patients taking immunosuppressants 
after organ transplantation. In developing countries, HIV infection emerged as a relatively 
                                                 
2 Quote from RABKIN et al. (2005; p. 11) 
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new chronic illness and the introduction of Highly Active Antiretroviral Therapy (HAART) 
placed a new emphasis on assessing adherence to HAART. Adherence has a significant 
impact on all outcome parameters of antiretroviral treatment: on plasma HIV RNA levels, 
on CD4+ lymphocyte count as well as on survival rates. Bangsberg et al. (2000) 
demonstrated a strong linear relationship between adherence to HAART and plasma HIV 
RNA levels, with a 10% decrease in adherence leading to a doubling of HIV RNA plasma 
levels. Among patients with undetectable HIV RNA load, adherence predicts the time that 
viral load is kept at undetectable levels (Raboud et al. 2002). Adherence was found to be 
significantly associated with successful virological outcome (Paterson et al. 2000) and an 
increase in CD4+ lymphocyte count (Singh et al. 1999). To the same extend that adequate 
adherence is linked to positive treatment outcomes, non-adherence can result in an 
increased viral load, emerging drug resistance that limits further treatment options, and, 
ultimately, in more rapid progression to clinical AIDS and increased mortality (Knobel et al. 
2001). 
There have been great concerns over whether the infrastructural, socio-economic and 
political difficulties in the countries of the developing world will allow for demanding and 
complicated treatment programs resulting in treatment success (Harries et al. 2001). The 
World Health Organization (WHO) advises that treatment principles in resource-limited 
settings be the same as for the developed world (WHO 2004); recent initiatives such as the 
Global Fund To Fight AIDS, Tuberculosis and Malaria (GFATM) and the Presidential 
Emergency Plan for AIDS Relief (PEPfAR) have provided funding to ensure availability and 
sustainability of antiretroviral treatment for these countries. Since the number of patients in 
developing countries is by far greater than in the developed world (UNAIDS 2008), these 
countries follow a public health approach in providing HAART for adults and children. The 
choice of antiretroviral drugs is limited, and fixed drug combinations are provided in so-
called first- and second-line regimens. The term first-line regimen describes the initial 
antiretroviral drug combination that a patient starts with. Upon the development of 
resistance to one or more of the drugs a switch to the second-line regimen, which includes 
different drugs, is possible. These fixed combinations do not allow the possibility for 
patient-individualized, “tailor-made” regimens as available in the developed world (WHO 
2005). In this way, the cost of antiretroviral drugs is reduced and treatment programs are 
more affordable and can allow for large amounts of patients. Given this limited choice of 
treatment options, the imperative of good adherence is of even greater importance in these 
settings. However, it has been contested whether or not good adherence would be possible. 
In a public statement made in 2001, the then chief of the U.S. Agency for International 
Development (USAID), Andrew Natsios, was quoted to have said that Africans “don’t know 
what Western time is” and thus could not take antiretroviral treatment on the proper 
schedule. Additionally he reportedly stated that when Africans were asked to take their 
drugs at a certain time of the day, they “do not know what you are talking about”3. This 
statement, implying that the culture and the general attitude of people living in African 
countries would render them unable to adhere to antiretroviral treatment, has been strongly 
condemned by patients, physicians and patients worldwide. In the following years, 
                                                 
3 See ATTARAN et al.: “Dead wrong on AIDS”. Published on 15th July 2001 in The Washington Post, 
United States. 
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numerous studies from resource-limited settings with HIV-infected adults and children 
taking HAART have highlighted that adherence is, in fact, rather good (Byakika-Tusiime et 
al. 2005; Nachega et al. 2004, Vreeman et al. 2008). In the first of two South African studies, 
Orrell et al. (2003) from Cape Town found that of 278 adults followed over 48 weeks, the 
median adherence was 94%, and concluded that low socio-economic status was not a barrier 
to achieving good adherence to antiretroviral triple therapy. In the other South African 
study Nachega et al. (2004) could show that 97% of HIV-infected adults receiving 
antiretroviral treatment at a public hospital in Johannesburg had adherence levels of greater 
than 90 percent. These findings are consistent with a meta-analysis comparing the adherence 
to antiretroviral treatment in patients from the United States to the adherence in patients 
from Sub-Saharan Africa, which found that the latter patient group showed higher pooled 
rates of adherence, and underlined the ability of African patients to adhere to their 
treatment (Mills et al. 2006).  
As lined out above, adherence in resource-limited settings is of even greater importance, yet 
may also be more difficult to achieve (Gill et al. 2005). In order not to jeopardize the limited 
options of treatment, virological suppression should be sustained for as long as possible. 
Emerging studies from various settings in resource-limited countries underline the findings 
by Mills et al. (2006) and show adherence rates that are as high or even higher than in the 
developed world (Byakika-Tusiime et al. 2005; Oyugi et al. 2004). In the context of these 
countries, structural and social inequalities have an unmistakable impact on the health 
status of patients. A recent report by the WHO Commission on Social Determinants of 
Health (CSDH 2008) indicates that the quality of urban and rural living conditions such as 
housing, sanitation and access to clean water are vital contributors to health. This should be 
borne in mind when comparing the outcomes of antiretroviral treatment in developing 
countries to outcomes from Europe and North America; it should also be borne in mind that 
the risk of treatment failure is higher when poorer health statuses exist, regardless of 
adherence. Since primary care health workers (physicians, nurses, pharmacists and 
community care workers) are at the forefront of the health care system, they often encounter 
the patient within her social and economic space. Primary care needs to take the social 
determinants of health into account, and the same applies to the social determinants of 
adherence. In order to do this, primary care providers need to know how to assess 
adherence in their patients. 
3. Assessing adherence in primary care 
Accurately measuring levels of adherence to medication has importance in clinical trials as 
well as in clinical practice. For clinical trials, the knowledge of patients actually taking the 
medication studied is imperative to allow examination of dose-response relationships and 
treatment efficacy. In clinical practice, the failure of a therapy to provide the desired clinical 
outcome can be due to either drug failure or poor adherence, and health care providers need 
information on adherence to make the adequate clinical decision. Most often, it is primary 
care providers who discuss the importance of adherence with their patients, and on whom it 
falls to assess whether patients adhere to their treatment plans or not. As with other chronic 
illnesses, in the case of HAART it is known that adherence levels decrease over time 
(Howard et al. 2002). The reasons for this are manifold and not difficult to imagine: 
treatment fatigue, forgetfulness, patients running out of medication, unforeseen 
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circumstances in which medication is not readily available, and, in less resourced countries, 
medication stock-outs at the point of distribution. Adherence monitoring is necessary to 
identify patients in need of adherence-improvement interventions before the clinical effects 
of non-adherence start to show. Measures in clinical settings should be effective, practical 
and inexpensive, with the aim of identifying poorly adherent patients. This is of even 
greater importance in resource-limited settings where limited treatment options often do not 
accommodate for drug changes that become necessary after the development of resistant 
viral strains due to poor adherence (Gill et al. 2005). Among the variety of available 
adherence measures, one can differentiate between direct and indirect measures (Farmer 
1999). Direct measures of adherence provide proof that the drug has been taken by the 
patient. There are two ways to achieve this: either by monitoring the drug (or its 
metabolites) in the patient's body, or by actually supervising the patient taking the drug. 
The former is called therapeutic drug monitoring, and drug metabolites are usually 
monitored in blood or urine, although often they can also be traced in other bodily fluids 
and even hair. This method requires knowledge of the pharmacokinetics of the studied drug 
and is an invasive procedure. Based on the drug plasma concentration the patient is 
classified as adherent or non-adherent. Therapeutic drug monitoring is often reserved for 
clinical trials, where the scientific interest justifies the invasive procedure to obtain the 
blood/ urine sample. Evidently, it requires a multitude of clinical resources (staff to take the 
sample and process it in an adequately equipped lab), and the results are not available 
immediately. On the other hand, directly-observed therapy (DOTS) – the monitoring of the 
actual intake of the drug by the patient – is relatively inexpensive and requires little to no 
resources. It is the basis of many successful tuberculosis treatment programs in the 
developing world. Often, it is carried out in the home of the patients – here, community care 
workers play a crucial role. While it requires a good infrastructure and availability of care 
workers (or even relatives) to supervise the patient taking her medication, the resources 
required from the health care system are minimal.  
Indirect measures of adherence can be categorized into subjective (self-reporting by the 
patient) and objective methods (medication measurement by pill count or estimation of 
liquid drug formulations, use of electronic monitoring devices and pharmacy prescription 
record review). These are the most common methods used in primary care settings and will 
be discussed in detail further on in this chapter.  
Each method has advantages and disadvantages that need to be weighed against each other. 
In general, the accuracy of measures is determined by calculating the sensitivity and 
specificity of the method with a standard of reference (Ransohoff and Feinstein 1978). For 
adherence measures, sensitivity denotes the proportion of adherent patients that are 
correctly identified as adherent. Specificity denotes the proportion of non-adherent patients 
rightly picked out as non-adherent; high specificity means that as few non-adherent patients 
as possible should be wrongly identified as adherent. The overall accuracy of the method is 
calculated by incorporating the proportion of patients that are correctly identified as 
adherent or non-adherent. However accurate one single measure of adherence may be, it is 
recommended to use a combination of measures to adjust for possible bias of each single 
method: “A multi-method approach that combines feasible self-reporting and reasonable 
objective measures is the current state-of-the-art in measurement of adherence behaviour.” 
(WHO 2003). A further way of validating adherence measures is by determining their 
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correlation with a surrogate marker of adherence. For HIV infection, undetectable HIV RNA 
plasma levels, indicating that HAART effectively works against the HI virus, serve as 
surrogate markers for adherence to HAART (Arnsten et al. 2001).  
3.1 Patient self-report 
Self report is an inexpensive and quick tool to assess adherence at a health care facility or at 
home. It can be administered by doctors or nurses, counsellors, social workers, clinical 
psychologists or community care workers. Depending on the relationship of the patient to 
the interviewer or the administering physician, results can vary in truth and reliability. Self 
report measures can be structured questionnaires asking about doses that were missed 
during a specified time before the clinic visit and thus quantifying non-adherence..These 
questionnaires can be handed out to the patients to be filled out anonymously. For patients 
with poor literacy or eye-sight, they can be read by the interviewer to assure that the 
information given is correct. Information on missed doses is used to classify patients or 
caregivers into adherent and non-adherent groups. Visual Analogue Scales (VAS, see Figure 
1) require patients to self-rate their adherence in percent and measure adherence as a 
continuous variable (Byrne et al. 2002; Giordano et al. 2004). Open interviews can highlight 
problems around adherence but make it more difficult to quantify adherence rates. A recent 
meta-analysis of various self-report measures in adult patients with HIV showed that in 85% 
of all studies reviewed, self-reported adherence was significantly associated with virological 
outcome (Simoni et al. 2006). There are numerous questionnaires that assess self-reported 
adherence. Visual Analogue Scales are among the most widely used self-reporting tools. 
Often abbreviated VAS, they combine the recollection memory with a visual component – 
patients are asked to rate their adherence on a scale. The scale, ranging from zero to one 
hundred percent, allows patients to estimate their adherence without forcing them to 
recollect specific drug intake moments. The visual component makes it suitable for patients 
who are less literate.  
While Visual Analogue Scales ask about drug doses that a patient has actually taken, 
questionnaires inquire about doses that a patient missed or forgot to take. Different formats 
of questionnaires span different recollection time intervals. It is common to ask for drug 
doses that were missed in the previous day, the previous three days, the previous week and 
the previous month. It is important to note that patients' memories become less accurate the 
longer the recollection time span is – a very understandable phenomenon, since who would 
remember forgetting to take medication 3 weeks ago? With the data gained from missed 
drug dose questionnaires, adherence rates can be calculated. This step might not necessarily 
be required in clinical practice, but is routinely used to standardise adherence rates in 
research. Questionnaires that are routinely used in HIV treatment adherence research are 
the ACTG and PACTG (for adult and paediatric missed drug dose recollection, 
respectively), developed by the AIDS Clinical Trial Group. These questionnaires are widely 
available and can serve as a blueprint for tailor-made self-report measures. 
An important limitation that needs to be noted for self-reported adherence measures is the 
inability to objectively confirm the information obtained from the patient. Self-report 
adherence measures are prone to over-reporting of adherence because patients often feel 
compelled to answer what they think the health care worker wants to hear. This social 
desirability (Simoni et al. 2007) can be caused by a lack of faith in the health care worker –  
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Fig. 1. A Visual Analogue Scale to assess HIV treatment adherence. 
patients fear that they would receive inferior treatment for not adhering well enough, or 
might feel ashamed at their 'failure' (Safren et al. 2006). This is an important issues especially 
in resource-limited settings where access to health care is limited, patients are less 
empowered and often depend on the only health care provider in the area. A trustful 
patient-provider relationship is key to ensuring that patients feel that they can be honest 
about their adherence behaviour, and it is imperative that health care providers remain non-
judgemental and keep encouraging patients to adhere rather than judge or penalise them for 
not adhering.  
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3.2 Pill count 
For pill count adherence measurement, patients are asked to return their unused medication 
at each clinic visit. A health care provider or researcher then calculates the percentage of 
prescribed pills that are absent from the medication container, thus enabling a measurement 
of adherence as a continuous variable (Steele et al. 2001). Pill count is a relatively quick and 
easy assessment of adherence, and once a patient has established the routine of returning 
unused medication, can be completed within a few seconds. For children who receive their 
medication in liquid form, the pill count concept is also applicable, although slightly more 
complicated. Upon return of the unused medication syrups, health care workers can 
measure the amount of liquid returned and calculate an adherence rate based on the amount 
of liquid the child had initially received. The accuracy of ill count assessment methods 
depends on the patient's cooperation in returning their unused medication.  
3.3 Electronic Monitoring Devices 
Electronic Monitoring Devices, also called EMDs are seen as the objective way to measure 
adherence. They are a relatively new assessment method that uses pressure-sensitive 
microchips, such as the Medication Event Monitoring System (MEMS), which is implanted 
in the caps of medication containers (Figure 2). The microchip records time and date of all 
bottle opening events as presumptive doses taken by the patient; the data is stored in the 
chip until downloaded onto a computer. MEMS caps allow the examination of patterns of 
adherence and detailed aspects of medication-taking, such as dose interval adherence, 
correct timing of dose-taking and prospective adherence assessment over time (Figure 3 
shows a sample analysis of data from a MEMS device). In HIV adherence research, MEMS 
caps are often used as a “gold standard” for adherence assessment in adults, because of a 
closer correlation with undetectable HIV RNA plasma levels than other single measures 
(Arnsten et al. 2001). Recently, MEMS caps have also been used to measure the adherence of 
children who take liquid medication (Müller et al. 2008).  
    
Fig. 2. MEMS container with cap and MEMS terminal to read the microchip 
Electronic Monitoring Devices have several advantages over more traditional adherence 
measures. Most outstanding is their ability to record not only adherence rates, but veritable  
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Fig. 3. A report by MEMS, an electronic monitoring device. The report is created with 
software and shows a) overall adherence statistics, b) drug doses taken by day, c) the 
chronology (timing) of doses taken and d) missed doses by day 
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adherence patterns. The microchip records the date and time of every container opening, 
and health care providers can trace each drug dose in detail. Hence, it is the only adherence 
measure that can record the exact time of drug dose taking – this is particularly important 
for drug regimen that depend on constant drug plasma levels, like antiretrovirals against 
HIV. The detailed report allows the health care worker to analyse together with the patient 
what the challenges to adherence are – for example if patients struggle more to keep 
medication times on weekends, or on certain days during the week. Often, these analyses 
reveal adherence challenges that patients were not aware of before. In this way, adherence 
assessment with Electronic Monitoring Devices also supports patients to adhere to their 
drug regimen. Newer electronic devices have evolved even more, and come with build-in 
timers and alarm clocks that serve as reminders to take drug doses. Another advantage of 
electronic devices is that they provide the most objective data of all indirect adherence 
measures. Similar to pill count, health care workers don't rely on information obtained from 
the patient, but can actually access adherence information directly from the microchip. 
Unlike pill count, the microchip is also more difficult to tamper with – because it measures 
medication-taking behaviour over the whole time in-between health facility visits, it cannot 
be changed or manipulated should patients try to do so before returning it to their health 
care worker.  
3.4 Pharmacy data 
Another way of assessing adherence is to record and analyse patient's patterns of obtaining 
refills and new prescriptions of their medication from pharmacies. Provided that patients 
either use the same pharmacy, or their records are stored in a central database – or that 
patients visit a pharmacy affiliated to the primary care facility – records on when patients 
pick up their renewed prescriptions gives an indication on how much of their previous 
medication they have taken. The presumption here is that patients who are adherent to their 
medication will use up all their stock in time for a new prescription (i.e. monthly 
prescriptions for HIV medication) and failure to adhere will lead to a surplus in medication 
that is reflected in late pharmacy pick ups. Another assumption is that a patient's adherence 
to scheduled pharmacy pick-ups is a surrogate marker for her medication adherence.  
An adherence rate is calculated in comparing the amount of doses prescribed and the 
amount of doses obtained from the pharmacy over a specified time period. This method is 
more applicable for large population-based studies where individual adherence rates are of 
less importance (Steiner and Prochazka 1997), but it can also be used to get an overview of 
individual patient's adherences. For HIV treatment adherence, it has been found to be 
correlated with virological outcome in adults (Grossberg et al. 2004; Low-Beer et al. 2000). 
4. Cost comparison of adherence measures - experience from South Africa 
In a recent study, a research team from the Desmond Tutu HIV Centre at the University of 
Cape Town set out to evaluate the cost-effectiveness and feasibility of a range of adherence 
measures at a paediatric primary care facility (Müller et al. 2010). In a cross-sectional study 
design, 53 paediatric patients were enrolled to have their adherence monitored by electronic 
monitoring devices, self-report by Visual Analogue Scale and missed-dose recall, by 
pharmacy refill data and by pill count (for most children this meant measurement of 
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returned syrups). The feasibility of each measure in a primary care setting was explored by 
its month-long use through primary care providers, and additionally a cost comparison of 
all measures was performed. The results highlighted crucial issues in the use of adherence 
assessment in primary care settings.  
The cost comparison of the adherence measures used an ingredients-based methodology in 
order to most accurately assess the cost of the measures (Drummond et al. 2005). This means 
measuring the utilization of staff time and measures (the ingredients) required to perform 
the task, and the cost of each measure. For each adherence measure all tasks performed by 
staff members over and above standard practice in the absence of adherence measurement 
were determined. For each task, a research assistant observed the clinic staff using the 
adherence measures, recording the time taken to perform the task and all consumables and 
other resources used. The costs of staff time were based on the annual cost of employment of 
the staff grade performing the task. The costs of other resources were based on their 
commercial prices with the costs of durable items being depreciated across their expected 
lifetime. Table 2 shows the costing of each adherence measure. It is quite clear that MEMS, 
the electronic monitoring device, was considerably more expensive than any of the other 
measures. This was primarily due to the high initial purchasing cost ($120 per cap; 
additionally the battery life limits the length of use to 3 years) but also due to high 
additional expected input from the pharmacist (annual wage $37,341) and pharmacist 
assistant (annual wage $8,487) in managing the adherence measurement process. All other 
measures were considerably cheaper, mostly because of the low cost of the required 
resources, but also because they could easily be carried out by lower qualified health care 
workers like health counsellors.  
 
Adherence monitoring method Resources 
Annual cost  
per patient 
1. Electronic Monitoring Device MEMS equipment $ 46.30 
 Staff time $ 11.53 
 Total cost $ 57.83 
2. Pharmacy Refill Data Staff time $ 2.58 
3. Visual Analogue Scale Staff time $ 0.19 
4. Missed dose questionnaire Staff time $ 0.39 
Table 2. Cost comparison of adherence measures 
5. Conclusion 
Continuous adherence to medication is crucial for therapeutic success for every medical 
condition. Adherence is always challenging, but even more so for chronic conditions that 
require patients to take their medication for long periods of time, or even life-long. In the 
recent 15 years, HIV treatment adherence has become one of the main adherence research 
areas, and it has added a new perspective on adherence issues, particularly in developing 
countries with limited resources to spend on health and patient support. Adherence 
assessment can occur at all levels of the health care system, but most often it is carried out 
by health care workers in primary care. This is not accidental – it is primary care workers 
that are most likely to know the patient and her social surroundings, and carry for 
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chronically ill patients in continuous care. Adherence is a team effort and requires constant 
commitment from patients – but also constant encouragement and support from health care 
workers. In order to recognise adherence challenges and potential adherence failures, health 
care workers need to monitor adherence systematically. This chapter has introduced the 
most common adherence measures in primary care, and highlighted their advantages and 
disadvantages. Clearly, every patient and every situation requires an individual assessment, 
and often the best adherence assessment is a combination of more than one measure. 
Perhaps more than anything else, issues around adherence speak to the challenges of 
leading a 'normal' life with a chronic illness, and highlight how patients integrate their 
illness (through their medication) into their daily lives. The implications of poor adherence 
or even non-adherence are often dire, and health care workers need to support patients by 
recognising early signs of poor adherence. Often this can be assessed in conversations with 
patients, but adherence measures provide a crucial tool to quantify and compare adherence 
in a more structured way.  
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